Janux Therapeutics, Inc. (JANX) stock
Close on Nov 12, 2026Market cap $702.77MP/E –Yield –
Janux Therapeutics, Inc. grew revenue 132.9% to $23.29M over the twelve months to Sep 30, 2026. Free cash flow was -$54.16M. At the latest close the market valued the company at $702.77M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $702.77M
- P/E ratio
- –
- Price to sales
- 30.18
- Price to book
- 0.77
- Dividend yield
- –
- Free cash flow yield
- -7.71%
Fundamentals
- Revenue
- $23.29M
- Net income
- -$99.85M
- EPS, diluted
- -$1.59
- Free cash flow
- -$54.16M
- Book value per share
- $14.45
- Diluted shares
- 63M
Trading
- Next earnings
- Feb 25, 2027 (estimated, during market hours)
- Previous close
- $12.39
- Open
- $11.86
- Day's range
- $11.45 – $11.99
- Volume
- 1,169,154
- Average volume (20 days)
- 1,049,671
- Index membership
- Russell 2000 (since Sep 2021), Russell 3000 (since Nov 2021)
- Beta (5 years)
- 1.57
- 52-week range
- $11.45 – $35.34
- RSI (14 days)
- 29.3
- Volatility (1 year)
- 77.5%
- Relative volume
- 1.31×
- WACC
- 12.8%
On 2 of our idea lists: Net-nets, More cash than they're worth
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | JANX | S&P 500 | Difference | JANX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -36.7% | -2.7% | −34.0 pts | ||
| 3 months | -31.0% | -1.7% | −29.3 pts | ||
| Year to date | -16.7% | +11.9% | −28.6 pts | ||
| 1 year | -59.7% | +12.0% | −71.7 pts | ||
| 3 years | +90.3% | +78.2% | +12.1 pts | +23.9% | +21.2% |
| 5 years | -48.9% | +73.2% | −122.1 pts | -12.6% | +11.6% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Janux Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Update
- Results
About Janux Therapeutics
Pharmaceutical Preparations
Janux Therapeutics is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer and autoimmune conditions. The company utilizes its proprietary TRACTr, TRACIr, and ARM technology platforms to create engineered bispecific molecules and T cell engagers. Its main clinical-stage candidates include JANX007, an investigational TRACTr therapy designed to treat metastatic castration-resistant prostate cancer, and JANX008, an EGFR-targeting TRACTr being evaluated across various solid tumor indications. In addition, the firm is advancing JANX011 for autoimmune diseases. While its clinical candidates are designed to treat patients, the company also engages with large biopharmaceutical collaborators such as Merck Sharp & Dohme and Bristol Myers Squibb.
Company profile, executives and historyJanux Therapeutics stock: common questions
What is Janux Therapeutics's stock price?
JANX closed at $11.49 on Nov 12, 2026, down 7.22% on the day. Over the past 52 weeks it traded between $11.45 and $35.34.
What is Janux Therapeutics's market cap?
Janux Therapeutics was worth $702.77M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is JANX's P/E ratio?
Janux Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.59), so it has no meaningful P/E ratio.
How much revenue does Janux Therapeutics make?
Janux Therapeutics reported revenue of $23.29M for the twelve months to Sep 30, 2026, up 132.9% from a year earlier.
Does Janux Therapeutics pay a dividend?
No. Janux Therapeutics has not paid a cash dividend over the last twelve months.
When does Janux Therapeutics report earnings next?
Janux Therapeutics is expected to report Q4 FY2026 results on Feb 25, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has JANX stock performed over the past year?
Including dividends, JANX returned -59.7% over the past year, against +12.0% for the S&P 500.
How many JANX shares are sold short?
5M shares were sold short at the latest FINRA report, 11.08% of the float, or 8.0 days of average trading volume.
Who are Janux Therapeutics's competitors?
Companies most similar to Janux Therapeutics by business, industry and size include CTMX, PRLD, PYXS, CUE, CBIO.
See a number that looks wrong?